BGE-102
Cardiovascular Risk Reduction
Key Facts
About BioAge Labs
Founded in 2015, BioAge Labs leverages its proprietary multi-omics discovery platform to translate insights from human aging biology into a pipeline of novel therapeutics for metabolic diseases. The company has achieved key milestones, including advancing its lead oral NLRP3 inhibitor, BGE-102, into Phase 1b/2a studies for cardiovascular risk and diabetic macular edema, and preparing an IND for its apelin receptor agonist as an exercise mimetic. Its strategy is validated by a recent $115 million public offering, positioning it to execute on its clinical and platform expansion goals through 2026.
View full company profileAbout BioAge Labs
Founded in 2015, BioAge Labs leverages its proprietary multi-omics discovery platform to translate insights from human aging biology into a pipeline of novel therapeutics for metabolic diseases. The company has achieved key milestones, including advancing its lead oral NLRP3 inhibitor, BGE-102, into Phase 1b/2a studies for cardiovascular risk and diabetic macular edema, and preparing an IND for its apelin receptor agonist as an exercise mimetic. Its strategy is validated by a recent $115 million public offering, positioning it to execute on its clinical and platform expansion goals through 2026.
View full company profileTherapeutic Areas
Other Cardiovascular Risk Reduction Drugs
| Drug | Company | Phase |
|---|---|---|
| Bempedoic Acid | Esperion Therapeutics (2) | Regulatory Review |
| Vascepa (icosapent ethyl) | Ligand Pharmaceuticals | Marketed |
| VASCEPA/VAZKEPA (Icosapent Ethyl) | Amarin Corporation | Approved |